Opening book details…
Can I read Trastuzumab conjugated porphyrin-superparamagnetic iron oxide nanoparticle: A potential PTT-MRI bimodal agent for herceptin positive breast cancer on EtoBox?
Trastuzumab conjugated porphyrin-superparamagnetic iron oxide nanoparticle: A potential PTT-MRI bimodal agent for herceptin positive breast cancer by Pegah Moradi Khaniabadi; Daryoush Shahbazi-Gahrouei; Azlan Abdul Aziz; Mohammed Ali Dheyab; Bita Moradi Khaniabadi; Baharak Mehrdel; Mahmood Subhi Jameel is a Medicine article available to read on EtoBox.
What is Trastuzumab conjugated porphyrin-superparamagnetic iron oxide nanoparticle: A potential PTT-MRI bimodal agent for herceptin positive breast cancer about?
Background: Theranostic agents can combine photosensitizers and contrast agents into a single unit for photothermal therapy (PTT) and magnetic resonance imaging (MRI). The possibility of treating and diagnosing malignant cancers without any ionizing radiation could become an option. This study investigates the theranostic potential of Fe 3 O 4 nanoparticles (IONs) for the diagnosis and treatment of cancer by developing a single integrated nanoprobe. Methods: Oleylamin-coated IONs (ION-Ol) were synthesized and surface of the IONs was modified using protoporphyrin (PP) and trastuzumab (TZ) to develop the TZ-conjugated SPION-porphyrin [ION-PP-TZ]. The structure, morphology, size, and cytotoxicity of all samples were investigated using Fourier-transform infrared spectroscopy (FT-IR), Transmission electron microscopy (TEM), X-ray powder diffraction (XRD), WST-1 assay, respectively. In addition to MRI and in vitro laser irradiation (808 nm, 200 mW) to determine the r 2 values and photothermal ablation. Results: The sizes of monodispersed nanoparticles were measured in rang 5.74-7.17 nm. No cytotoxicity was observed after incubating MCF 7 cells under various Fe concentrations of nanoparti
Who reads Trastuzumab conjugated porphyrin-superparamagnetic iron oxide nanoparticle: A potential PTT-MRI bimodal agent for herceptin positive breast cancer?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Pegah Moradi Khaniabadi; Daryoush Shahbazi-Gahrouei; Azlan Abdul Aziz; Mohammed Ali Dheyab; Bita Moradi Khaniabadi; Baharak Mehrdel; Mahmood Subhi Jameel
- Publisher
- Elsevier BV
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)